In a 23‑week pregnant woman with multiple T2‑hyperintense liver lesions (a 1.7 cm lesion in the left hepatic lobe and two lesions up to 1.3 cm in the posterior right hepatic lobe) on abdominal MRI, what are the recommended next steps for evaluation and management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 1, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Management of T2-Hyperintense Liver Lesions in a 23-Week Pregnant Woman

These lesions most likely represent benign focal nodular hyperplasia (FNH) or hemangiomas, and imaging is not routinely required for FNH during pregnancy, while ultrasound surveillance each trimester is recommended for hemangiomas, particularly those that are large or peripherally located.

Differential Diagnosis and Risk Stratification

The moderately T2-hyperintense lesions measuring 1.3-1.7 cm in this pregnant patient most commonly represent:

Most Likely: Focal Nodular Hyperplasia (FNH)

  • FNH has a benign course in pregnancy and does not increase maternal or fetal risk 1
  • Pregnancy is not contraindicated and vaginal delivery carries no increased risks 1
  • Routine imaging surveillance is NOT recommended for FNH during pregnancy 1

Alternative: Hemangiomas

  • These are the most common benign liver tumors (prevalence 0.4-7.3%, female predominance) 1
  • For hemangiomas <4 cm and centrally located: low risk of complications
  • For hemangiomas ≥4 cm, peripherally located, or exophytic: ultrasound assessment each trimester is recommended 1
  • Risk of rupture in giant hemangiomas (>4 cm) is approximately 3%, increasing to 5% for lesions >10 cm 1

Less Likely but Important to Exclude: Hepatocellular Adenoma (HCA)

  • HCA <5 cm: no increased complication risk, but ultrasound assessment each trimester is recommended to monitor for growth 1
  • HCA ≥5 cm carries 25-30% bleeding risk and should ideally be treated before pregnancy 1
  • Your patient's lesions are all <2 cm, making significant HCA-related complications unlikely

Recommended Management Algorithm

Immediate Steps:

  1. Review clinical history for:

    • Oral contraceptive use (increases HCA risk)
    • Known pre-existing liver lesions
    • Symptoms: right upper quadrant pain, nausea beyond typical pregnancy symptoms
    • Risk factors for cirrhosis or hepatocellular carcinoma (chronic hepatitis B/C, alcohol use)

  2. Review MRI characteristics more carefully:

    • Central scar suggests FNH
    • Homogeneous high T2 signal suggests hemangioma
    • Heterogeneous appearance or fat content suggests HCA

Surveillance Strategy:

If imaging characteristics favor FNH:

  • No routine follow-up imaging required 1
  • Reassure patient that pregnancy and vaginal delivery are safe
  • Monitor clinically for symptoms only

If imaging characteristics favor hemangioma:

  • Ultrasound surveillance each trimester (currently at 23 weeks, repeat at ~30-32 weeks and ~36-38 weeks) 1
  • Focus on assessing size changes and location (peripheral/exophytic lesions carry higher rupture risk)
  • Given all lesions are <2 cm and likely centrally located, risk is very low

If imaging is indeterminate or suggests HCA:

  • Ultrasound surveillance each trimester to monitor for growth 1
  • Growth >20% or increase to >5 cm warrants multidisciplinary discussion
  • Consider transarterial embolization if rapid growth occurs (safe in pregnancy) 2

Delivery Planning:

  • Vaginal delivery is not contraindicated for FNH or small hemangiomas 1
  • For hemangiomas approaching 4-5 cm or if HCA grows significantly, consider:
    • Elective cesarean section to avoid prolonged second stage
    • Assisted delivery to minimize Valsalva maneuvers
    • Delivery at tertiary center with hepatobiliary surgery capability

Key Clinical Pitfalls to Avoid

  1. Do not withhold necessary imaging due to pregnancy 3—MRI without contrast is safe and appropriate
  2. Do not assume all T2-hyperintense lesions are the same—characterization matters for surveillance decisions
  3. Do not perform routine surveillance for FNH—this creates unnecessary anxiety and healthcare costs 1
  4. Do not ignore rapid growth—any lesion growing to >5 cm requires intervention consideration 1

Postpartum Considerations

  • Repeat imaging 3-6 months postpartum to establish new baseline, as pregnancy-related hormonal effects will resolve
  • Many lesions (particularly HCA) may decrease in size after delivery
  • If lesions remain stable and characteristics favor FNH, no further surveillance needed
  • If characteristics favor hemangioma or HCA, continue standard non-pregnancy surveillance protocols

The most important immediate action is to determine whether these lesions represent FNH (requiring no surveillance) versus hemangiomas or HCA (requiring trimester ultrasound monitoring). Given the size (<2 cm) and typical T2 characteristics, maternal and fetal prognosis is excellent regardless of final diagnosis.

References

Related Questions

What is the minimum recommended duration of antimicrobial therapy for a deep puncture wound?
A 10‑day postpartum woman presents with dysuria and a urine culture growing mixed microbiota >100,000 CFU/mL; how should this be managed?
What is the appropriate 10‑day antibiotic regimen for a patient undergoing ENT follow‑up after image‑guided fine‑needle aspiration/biopsy, assuming no documented β‑lactam allergy?
In a 10‑month‑old infant with a slightly indented coronal suture, normal fontanelles, and appropriate head growth, what is the appropriate next step in management?
Should an asymptomatic urine culture with 10,000–49,000 CFU/mL Escherichia coli be treated?
What is Tab Thyronorm (levothyroxine)?
What are the recommended aliquot volumes and monitoring guidelines for administering blood product transfusions (red cells, platelets, plasma) in infants?
When should a pharmacist refer a patient with dermatitis to a prescriber for further medical evaluation?
Which glucagon-like peptide‑1 (GLP‑1) receptor agonist is approved for metabolic dysfunction‑associated steatotic liver disease (MASLD) in India?
What is the appropriate duration of antibiotic therapy after surgical drainage of a pancreatic or intra‑abdominal abscess in an adult?
What are the 2025 American Heart Association/American College of Cardiology (AHA/ACC) hypertension guidelines and the older JNC 6 hypertension guidelines?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.